An Investigational Immuno-therapy Study of Nivolumab, or Nivolumab in Combination With Ipilimumab, or Placebo in Patients With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based Chemotherapy
Public ClinicalTrials.gov record NCT02538666. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
In this study, all patients must have already completed first-line chemotherapy to treat extensive-stage disease small cell lung cancer. The purpose of this study is to show that nivolumab, or nivolumab plus ipilimumab followed by nivolumab by itself, will prolong overall survival when administered as consolidation treatment in patients that are stable or responding after chemotherapy. Patients receiving treatment will be compared with patients taking placebo.
Study identification
- NCT ID
- NCT02538666
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 907 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Oct 13, 2015 (Actual)
- Primary completion
- Oct 1, 2018 (Actual)
- Completion
- Nov 11, 2021 (Actual)
- Last update posted
- Jan 5, 2023
2015 – 2021
United States locations
- U.S. sites
- 28
- U.S. states
- 20
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0003 | Sacramento | California | 95816 | — |
| Local Institution - 0202 | New Haven | Connecticut | 06520 | — |
| Local Institution - 0127 | Fort Myers | Florida | 33901 | — |
| Local Institution - 0007 | Jacksonville | Florida | 32256 | — |
| Local Institution - 0128 | St. Petersburg | Florida | 33705 | — |
| Local Institution - 0010 | Atlanta | Georgia | 30322 | — |
| Local Institution - 0013 | Indianapolis | Indiana | 46237 | — |
| Local Institution - 0061 | Fairway | Kansas | 66205 | — |
| Local Institution - 0012 | Wichita | Kansas | 67214 | — |
| Local Institution - 0032 | Lexington | Kentucky | 40503 | — |
| Local Institution - 0051 | Baltimore | Maryland | 21287 | — |
| Local Institution - 0107 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0207 | Boston | Massachusetts | 02215 | — |
| Local Institution - 0015 | St Louis | Missouri | 63110 | — |
| Local Institution - 0008 | New York | New York | 10065 | — |
| Local Institution - 0014 | Durham | North Carolina | 27710 | — |
| Local Institution - 0016 | Winston-Salem | North Carolina | 27103 | — |
| Local Institution - 0215 | Fargo | North Dakota | 58102 | — |
| Local Institution - 0129 | Cincinnati | Ohio | 45242 | — |
| Local Institution - 0009 | Columbus | Ohio | 43210 | — |
| Local Institution - 0001 | Portland | Oregon | 97213 | — |
| Local Institution - 0034 | Portland | Oregon | 97239 | — |
| Local Institution - 0004 | Allentown | Pennsylvania | 18103 | — |
| Local Institution - 0002 | Sayre | Pennsylvania | 18840 | — |
| Local Institution - 0005 | Charleston | South Carolina | 29425 | — |
| Local Institution - 0213 | Sioux Falls | South Dakota | 57104 | — |
| Local Institution - 0011 | Salt Lake City | Utah | 84112 | — |
| Local Institution - 0006 | Richmond | Virginia | 23226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 169 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02538666, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 5, 2023 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT02538666 live on ClinicalTrials.gov.